



Faculty disclosures report

The 2026 COMy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COMy participants. In doing so, the 2026 COMy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all its scientific, educational, and advocacy activities and materials.

Educational Content Development

The 2026 COMy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The 2026 COMy Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2026 COMy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2026 COMy Congress of CME based on the CME providers of the Congress.

All 2025 COMy Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2026 COMy Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

2026 COMy Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Consultant	C
Advisory Boards	A
Research Funding	R
Speakers' Bureau	S
Employee	E
Other	<i>Written as stated on submitted form</i>
Nothing to declare	<i>Written as said statement</i>



Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Kenneth Anderson, USA

C Astra Zeneca, Janssen, Pfizer, Genentech-Roche
A Dynamic Cell Therapies, C4 Therapeutics, Starton, Window, Predicta

Nizar Bahlis, Canada

H,C,A AbbVie, BMS, J&J, Genentech, Pfizer, GSK, Sanofi

Susan Bal, USA

Nothing to declare

Joan Bladé, Spain

Nothing to declare

Arthur Bobin, France

Nothing to declare

Emilie Chalayer, France

A BMS
R LeoPharma

Jill Corre, France

H Janssen, BMS, Pfizer, Adaptive, Amgen, AbbVie, Sanofi

Madhav Dhodapkar, USA

A BMS, Sanofi, Novab Therapeutics

Meletios Dimopoulos, Greece

H,C,A Amgen, Sanofi, Regeneron, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca

Hermann Einsele, Germany

H,C,A BMS, J&J, Amgen, Takeda, Sanofi, GSK, Novartis
R BMS, J&J, Amgen, GSK, Sanofi

Carlos Fernández de Larrea, Spain

H Amgen, J&J, BMS, GSK, Sanofi, Pfizer, Beigene, Miltenyi
A J&J, BMS, Amgen, Pfizer, Sanofi, Beigene, GSK, Roche, Menarini
R BMS, J&J, Amgen, GSK

Irene Ghobrial, USA

C AbbVie, Adaptive, Amgen, Aptitude Health, Arcellx, Astra Zeneca, BioSkrby Genomics, BMS, Civala Inc, Clinical Care Options, Clinical Education Alliance, ENGAGE, Feromics Inc, Genentech, GSK, Janssen, Kite Pharma, Menarini, ONK Therapeutics, Pfizer, Regeneron, Sanofi, Silicon Biosystems, Takeda, TG Therapeutics, Window
H Amgen, Curio Science, Janssen, MD Education, MJH Life Sciences, Physicians Education Resource, Regeneron, Standard Biotools, Takeda, Thermo Fischer/Binding Site, Veeva, Vor Biopharma
Other Predicta Biosciences, Disc Medicine

Martin Kaiser, UK

C AbbVie, BMS/Celgene, J&J, GSK, Karyopharm, Kite, Pfizer, Poolbeg, Regeneron, Roche, Sanofi, Takeda
H AbbVie, BMS/Celgene, J&J, GSK, Sanofi, SkylineDx, Takeda
R BMS/Celgene



Shaji Kumar, USA

Nothing to declare

Suzanne Lentzsch, USA

C BMS, J&J

A Pfizer, BMS, J&J, Sanofi, GSK, Kite

Sagar Lonial, USA

A Takeda, Amgen, Novartis, BMS, GSK, AbbVie, Genentech, Pfizer, Regeneron, Janssen

R Novartis, BMS, Janssen, Takeda

Other TG Therapeutics

Florent Malard, France

H Sanofi, Amgen, Novartis, BMS, Astra Zeneca, Therakos, Prithera, MSD, Orcabio

Salomon Manier, France

C,A,R AbbVie, Adaptive, Amgen, BMS/Celgene, GSK, Janssen, Kite, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda

S Janssen

Joaquín Martínez López, Spain

C,A,S J&J, BMS, Pfizer, Menarini, Gilead, GSK

R BMS, Incyte

María-Victoria Mateos, Spain

H,J J&J, BMS, Amgen, GSK, Sanofi, Pfizer, Roche, AbbVie, Kite, Stemline-Menarini, Oncopeptides

C J&J, BMS, GSK, Pfizer, Kite

Francesco Maura, USA

C Sanofi, Medidata

Philippe Moreau, France

H, A Janssen, BMS, Pfizer, GSK, Sanofi, Takeda, Amgen, AbbVie

Nikhil Munshi, USA

Nothing to declare

Paola Neri, Canada

H,C,A BMS, Sanofi, Pfizer, J&J, GSK

Aurore Perrot, France

H AbbVie, Adaptive, Amgen, BMS, GSK, J&J, Menarini Stemline, Pfizer, Sanofi, Takeda

Noemi Puig, Spain

Nothing to declare

Vincent Rajkumar, USA

Nothing to declare

Paul Richardson, USA

C BMS/Celgene, GSK, Karyopharm, Oncopeptides, Regeneron, Sanofi

R Oncopeptides, Karyopharm



The 12th World Congress on Controversies in Multiple Myeloma (COMy)
May 14-17, 2026 - Paris, France & Online
comy.cme-congresses.com

Jesús San Miguel, Spain

C,A Amgen, BMS, Celgene, Janssen, MSD, Novartis, Sanofi, Roche, GSK, Karyopharm, AbbVie, SecuraBio, Regeneron, Pfizer

Pieter Sonneveld, Netherlands

Nothing to declare

Keith Stewart, Canada

C BMS, J&J

A Pfizer, Sanofi, J&J, Kite

Uriel Suárez, Spain

Nothing to declare

Evangelos Terpos, Greece

H GSK, J&J, Sanofi, Takeda, BMS, Lilly, Pfizer, Swixx, Amgen, Antengene, EUSA Pharma, Forus, Menarini Stemline

A GSK, J&J, Sanofi, Takeda, BMS, Lilly, Pfizer, Swixx

R GSK, J&J, Sanofi, Takeda

Cyrille Touzeau, France

H,C,A J&J, BMS, Pfizer, Sanofi, AbbVie, Menarini, Amgen, GSK

Steven Treon, USA

H AbbVie, BeOne Medicine

CA, BeOne Medicine

R AbbVie, GSK/Parexcel, Sanofi

Saad Usmani, USA

C AbbVie, Amgen, BMS/Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuroBio, SkylineDX, Takeda, TeneoBio

R AbbVie, Amgen, Array Biopharma, BMS/Celgene, GSK, Gilead, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

Kwee Yong, UK

Nothing to declare

Elena Zamagni, Italy

H,C,A,S Janssen, BMS, Sanofi, Amgen, GSK, Pfizer, Oncopeptides, Menarini Stemline, Roche, Astra Zeneca